Calaspargase pegol for ALLFebruary 5, 2019
The US FDA has cleared calaspargase pegol-mknl for acute lymphoblastic leukaemia as part of a multiagent chemotherapeutic regimen for paediatric and young adult patients.
Calaspargase pegol-mknl (Asparlas) is an asparagine specific enzyme that is proven to have a longer interval between doses compared with other approved pegaspargase products. Cal-PEG would provide a treatment that has an extended shelf life beyond that of the current PEGylated asparaginase treatment, helping ensure availability to patients.
The corresponding study that supported the approval analysed the drug with multiagent chemotherapy in 124 patients with B-cell lineage ALL.